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Background:  The  number  needed  to vaccinate  (NNV)  is a  measure  that  has  been  widely  used  in the scien-
tiﬁc  literature  to  draw conclusions  about  the  usefulness  and  cost-effectiveness  of various  immunization
programmes.  The  main  objective  of this  review  is to  examine  how  and  why  the  NNV  has  been  used  and
reported  in  the  published  literature.
Methods:  Electronic  databases  were  searched  and  records  were  screened  against  the  eligibility  criteria
by  two  independent  authors.  We  included  papers  that reported  and  interpreted  NNV.
Results:  We  identiﬁed  27 studies,  the designs  including  observational  studies,  economic  analyses,  sys-
tematic  reviews,  and  commentaries.  The  NNV  has  been  used  in  the  literature  to  describe  three  mainumber needed to vaccinate
ost-effectiveness
athematicalmodelling
umber needed to treat
eneﬁts of vaccination
themes:  potential  beneﬁts  of vaccination  programmes,  cost-effectiveness,  and  economic  analyses,  and
modelling  studies  to compare  different  vaccination  strategies.
Conclusions: NNV  has  been  used  in a wide  variety  of  ways  in  the  literature,  yet there  are no deﬁned
thresholds  for what  is  a favourable  NNV.  Furthermore,  the  generalizability  of  the  NNV  is  usually limited.
Further  work  is  required  to  determine  the most  appropriate  use of  this  measure.
Crown  Copyright  © 2015  Published  by  Elsevier  Ltd. This is  an  open  access  article  under  the
CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Vaccines have saved more lives than any other health interven-
ion in the last century. The World Health Organization estimates
hat more than two million deaths annually are prevented due to
mmunization programmes worldwide [1]. Despite this measur-
ble impact, the beneﬁts of immunization are sometimes taken
or granted, which can pose a signiﬁcant challenge [2,3]. Sustain-
ng the priority of vaccine-preventable diseases in the eyes of the
ublic and policy makers is more difﬁcult when these diseases are
ell-controlled because they are out of sight and therefore out of
ind. The beneﬁts of immunization need to be promoted using
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N.S. Crowcroft).
1 Present address: University of British Columbia, School of Population and Public
ealth, Faculty of Medicine, 2206 East Mall, Vancouver, BC Canada V6T 1Z3.
ttp://dx.doi.org/10.1016/j.vaccine.2014.12.033
264-410X/Crown Copyright © 2015 Published by Elsevier Ltd. This is an open acces
y-nc-nd/3.0/).simple and intuitive measures that enable fair comparison with
other competing priorities.
The number needed to vaccinate (NNV) is used as a simple sum-
mary calculation to evaluate the possible beneﬁts of immunization
programmes in preventing and controlling communicable diseases.
It is deﬁned as the number of persons needed to vaccinate in order
to prevent one outcome, and it combines both vaccine effectiveness
and incidence of disease [4]. Generally, the NNV is calculated as
NNV = 1/(annual incidence of event in the unvaccinated × vaccine
effectiveness (VE)). This is equivalent to the reciprocal of the annual
absolute risk reduction, since the VE measures the relative risk
reduction. [4]
In recent years there have been an increasing number of analy-
ses that use NNV to evaluate the usefulness and cost-effectiveness
of several vaccines. Although NNV is an intuitive measure of the
beneﬁt of a given vaccine, there remains no agreed threshold for
interpreting this number, and questions have been raised as to
whether it is an appropriate measure [31]. This systematic review
aims to explore how and why NNV is used in the scientiﬁc literature
in order to draw conclusions about the appropriate use of NNV for
public health decision making.
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Table 1
Number of studies by study design and vaccine type.
Characteristics Number of studies
Study design
Observational studies 9
Economic evaluation 7
Systematic reviews +/− Meta-analysis 6
Commentary 3
Modelling 2
Vaccine type
Inﬂuenza 8
Tuberculosis 4
Herpes Zoster (HZ) 3
Human Papilloma Virus (HPV) 3
Pertussis 3
Hepatitis A 2
Pneumococcal 2
Meningococcal B (MenB) 1
Respiratory Syncytial Virus (RSV) 1
Rabies 1
Outcome
Case 20
Death 7
Hospitalization 6
Outpatient visit 1
Quality-adjusted life year (QALY) 154 A. Hashim et al. / Va
. Methods
We  searched the online databases MEDLINE, EMBASE, and
INAHL in February 2013 for all primary research studies that have
eported, calculated, and interpreted NNV. We  included all review
rticles, commentaries, and published letters that reported and
nterpreted NNV. Studies that did not interpret NNV were excluded.
earch strategy was restricted to English-language publication on
uman subjects. Eligibility criteria were applied to examine all the
ecords at the title, abstract, and full text stages. This was conducted
ystemically by two reviewers (AH and VD) using Microsoft® Ofﬁce
xcel® 2007 version 12 (Microsoft Corporation, Richmond, USA).
iscrepancies between the two reviewers were resolved through
onsensus. If the title or abstract of a given study was not enough
o determine inclusion or exclusion from our study, the full texts
ere assessed against the same criteria. In addition, the references
f all articles were reviewed for other potentially eligible studies.
he search strategy used the following terms: “number-needed-to-
accinate” or “NNV” or “prevent case or illness or death or outcome
r event or disease or hospitalisation or hospitalization” and “vacci-
ation or immunisation or immunization”. Data extracted from the
ligible studies comprised of study objectives, study design, NNV
eﬁnition, vaccine type, disease outcome, population characteris-
ics, parameters used in calculating NNV, vaccine effectiveness, and
nterpretation.
. Results
.1. Study selection and characteristics
The initial search resulted in 432 entries, of which 11 were dupli-
ates; 393 were excluded on the basis of our screening criteria at
he title and abstract stage. At the full-text screening stage, ﬁve
ecords were excluded for not meeting the inclusion criteria. Ref-
rence and citation tracking identiﬁed an additional four eligible
apers, providing a total of 27 papers for review. Fig. 1 illustrates a
ow diagram of the study selection process.
The disease outcomes reported were inﬂuenza in eight stud-
es [4–11], tuberculosis in four studies [12–15], as well as three
tudies each of herpes zoster (HZ) [16–18], human papilloma virus
HPV) [19–21], and pertussis [22–24]. Two studies each focused
n Hepatitis A [25,26] and pneumococcal disease [4,27]. Other
isease outcomes included serogroup B meningococcal disease
28], respiratory syncytial virus (RSV) [29], and rabies [30]. Out-
omes for which NNVs were measured included being a case of
 speciﬁc disease, death, hospitalization, outpatient visit, quality-
djusted life year (QALY), disability-adjusted life year (DALY),
nd life-years lost. One third of the included studies (n = 9) used
ata from observational studies, which were primarily cohort
tudies [8–10,12,17,23,27,28,30]. In addition, seven studies were
ost-effectiveness and economic analyses [4,5,13,15,16,21,22], six
tudies were systematic reviews [6,7,11,14,26,29]; three were
ommentaries [18,20,25], and two studies utilized mathematical
odelling [19,24]. Study characteristics of the included studies are
ummarized in Table 1.
.2. How is NNV being used in the literature?
.2.1. Potential health-related beneﬁts of vaccination
rogrammes
Fourteen studies (52%) used NNV as a measure of potential ben-
ﬁts of vaccination programmes.
Of these, ﬁve articles in the literature utilized NNV to measure
he potential beneﬁt of inﬂuenza vaccination using different health
utcomes. Kelly and colleagues [10] quantiﬁed the beneﬁts of anDisability-adjusted life year (DALY) 1
Life-years lost 1
inﬂuenza vaccination programme by calculating the number of per-
sons required to be vaccinated to avoid one hospital admission due
to inﬂuenza. They reported that 1852 children would have to be
vaccinated to avoid one hospitalization due to any strain of circu-
lating inﬂuenza in 2009. Lewis and colleagues also quantiﬁed the
numbers of children who  needed to be vaccinated to prevent one
hospitalization and outpatient visit [7]. This was found to range
from 1031 to 3050 for children 6–23 months of age and from 4255
to 6897 for children 24–59 months of age. They estimated that
12–42 children 6–59 months of age need to be vaccinated to pre-
vent one outpatient visit, and that vaccination was  therefore an
important means of reducing inﬂuenza associated outpatient visits
in this age group. Similarly, two other studies used NNV to measure
the beneﬁts of inﬂuenza vaccination in preventing inﬂuenza and
cases of inﬂuenza-like illness in pregnancy and postpartum women,
and HIV-infected individuals, respectively [8,11]. Voordouw and
colleagues investigated the beneﬁt of inﬂuenza vaccination for pre-
venting all-cause mortality. The authors stated that in order to
prevent one death due to inﬂuenza, it is required to vaccinate 302
individuals or one for every 195 repeated vaccinations at a vaccina-
tion coverage up to 74%. They concluded that the annual inﬂuenza
immunization of the elderly population has the potential to reduce
all-cause mortality [9].
Two studies used NNV to evaluate the potential beneﬁts against
HZ. Skootsky described the NNV as an alternate measure of efﬁcacy
against HZ [18]. It was reported that one case of HZ was avoided
for every 175 adults over 60 years of age who were vaccinated, and
one prevented for every 231 adults 70 years of age or older. A simi-
lar analysis for patients 70 years and older showed that 231 people
needed to be vaccinated to prevent one episode of HZ. Skootsky
concluded that these numbers are greater than what many physi-
cians and most patients might expect (although what would be
expected was  not deﬁned precisely) and therefore a less attractive
HZ vaccination programme. In another HZ study, Brisson [17] esti-
mated the NNV for various HZ related health outcomes for patients
who are 65 years. Brisson estimated that the NNV to prevent a case
of HZ is 11, to prevent a case of post herpetic neuralgia (PHN) is
43, to prevent an HZ death is 23,319, to prevent a life-year lost
is 3762, and to prevent a lost QALY is 165. The study stated that,
A. Hashim et al. / Vaccine 33 (2015) 753–758 755
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aig. 1. Flowchart showing literature search strategy. Medline, EMBASE and CINAH
ecords were screened. Of these, 27 met  the criteria for inclusion in this review.
ince the NNV to prevent a QALY lost is signiﬁcantly less than the
NV to prevent a life-year lost, the main beneﬁt of HZ vaccination
s the prevention of pain and suffering, rather than mortality. The
tudy concluded that the NNV can be used intuitively by clinicians
o inform their patients of the potential beneﬁts of HZ vaccina-
ion and by public health ofﬁcials as a measure of the preventable
urden of disease through vaccination [17].
Several other studies were conducted to evaluate the beneﬁts of
accination against other diseases. Kelly et al. reported a NNV of 646
o prevent one case of tuberculosis in 1986, and 551 in 1991. They
oncluded that this evidence supports a policy of continued neona-
al Bacillus Calmette-Guérin (BCG) vaccination in the population of
he Republic of Ireland [12]. One study from the UK reported that
206 persons are required to be vaccinated to prevent one inva-
ive pneumococcal disease. In this study, NNV was communicated
s an alternative way to demonstrate the overall effectiveness of
he vaccination programme [27]. An editorial by Sawaya and Smith
alculated the NNV for a clinical trial (FUTURE II) that measured
PV vaccine efﬁcacy. It was found that 129 persons needed to be
accinated against HPV in order to prevent one case of cervical
ntraepithelial neoplasia [20].
Dang et al. calculated the NNV for serogroup B meningococcal
isease, and estimated that between 33,784 and 38,610 infants
ould need to be vaccinated in order to prevent one case of
erogroup B invasive meningococcal disease. The number would
e even higher to between 123,751 and 141,429 if cases in infants
nder six months of age were assumed to not be vaccine pre-
entable. The authors concluded that this was very high and made
he vaccine unlikely to be an attractive policy option. Since there
re currently no licensed meningococcal B vaccines in Canada, the
alculations in this study were mainly based on several assump-
ions including hypothetical vaccine efﬁcacy and vaccine uptake,
nd an assumption that there was no herd immunity, resulting in
 conservative NNV estimate [28].abases were searched for appropriate literature. After removal of duplicates, 421
Crowcroft calculated the number of households that need to
be vaccinated with hepatitis A vaccine instead of human normal
immunoglobulin (HNIG) to prevent one secondary case of hepatitis
A. The study found that 8–26 persons would need to be vaccinated
to prevent an additional secondary case. Such signiﬁcantly worse
outcomes were unlikely to be observable by public health profes-
sionals in the context of very low disease incidence [25]. In this
study, NNV was used to evaluate the ability of the public health
system to distinguish between the effectiveness of different inter-
ventions.
In addition to primary studies utilizing the NNV to describe
the potential beneﬁts of vaccination programmes, two system-
atic reviews and meta-analyses were identiﬁed. Jefferson and
colleagues conducted a systematic review and meta-analysis to
measure inﬂuenza vaccine effectiveness and efﬁcacy in healthy
children [6]. They used NNV to compare prevention of laboratory
conﬁrmed inﬂuenza by live attenuated vaccine with that of inactiv-
ated vaccines and reported an NNV of seven for live attenuated and
an NNV of 28 for inactivated vaccine. Simoes and colleagues [29]
conducted a systematic review and meta-analysis of clinical trials
of experimental RSV vaccines for individuals 12 months and older
to explore whether RSV vaccines are efﬁcacious in preventing RSV
lower respiratory tract infection, but conclusions were limited by
heterogeneity between studies.
3.2.2. Cost-effectiveness analysis
Eleven studies (41%), including seven economic analyses
[4,5,13,15,16,21,22], two observational studies [23,30] and two
systematic reviews [14,26] interpreted NNV in the context of a
cost-effectiveness analysis of vaccination programmes.Three studies identiﬁed in the literature measured the cost
effectiveness of tuberculosis vaccination programmes. Trunz and
colleagues conducted a systematic review to assess the cost-
effectiveness of childhood immunization programmes to prevent
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uberculosis meningitis and severe tuberculosis worldwide [14].
hey estimated that around 150,000 children should be vaccinated
o prevent one case of tuberculosis. The authors commented that
mmunization programmes against tuberculosis are cost-effective
o prevent and control childhood tuberculosis particularly in high-
ncidence countries. In another study in the Netherlands, it was
stimated that around 9000 would need to be vaccinated to
revent one severe tuberculosis infection. They presented their
esults in terms of cost/DALY to be spent on vaccination; NNV for
he target group corresponded to D 4500/DALY, which lies below
he threshold considered “reasonable” for public health interven-
ion, thus it was  concluded that the immunization programme in
etherlands is cost-effective [13]. On the other hand, Rahman et al.
onducted a cost-effectiveness analysis of the Japanese BCG vacci-
ation programme. This study estimated that between 2125 and
0,399 immunizations at the cost of US $35,950–$175,862 would
e required to prevent one case of tuberculosis. They concluded
hat universal BCG vaccination programme is not cost-effective
pproach since the immunization cost was higher than the cost
equired to treat one patient with tuberculosis infection [15].
Two studies have assessed cost-effectiveness using NNV of the
cocooning’ immunization strategy, whereby parents and other
lose contacts of an infant are vaccinated with tetanus, diphthe-
ia and acellular pertussis vaccine, to protect newborn infants from
ertussis infection. Meregaglia et al. estimated that at least 5000
arents needed to be vaccinated, at a total cost of more than
 100,000 to prevent one pertussis-related hospitalization. They
oncluded that the parental cocoon strategy is not a cost-effective
pproach in preventing pertussis in this age group [22]. Likewise,
kowronski and colleagues reported that the NNV for the cocooning
mmunization strategy against pertussis was around one million to
revent one infant death and approximately 10,000 for hospitaliza-
ion. Like Meregaglia and colleagues, they described the cocooning
mmunization programme as a non-cost effective strategy [23]. In
nother study, similar in considering a targeted strategy for a high
isk group, Rowe et al. evaluated the use of routine hepatitis A
accination in hepatitis C infected persons, concluding that it is
ostly and its incorporation into clinical practice guidelines is not
ecommended [26].
Kelly and colleagues conducted a cost-effectiveness analysis to
ompare the potential beneﬁts of the inﬂuenza and pneumococ-
al vaccination programmes in the elderly population. Although
he cost to prevent a case of inﬂuenza infection per year is less
han the cost to prevent a case of invasive pneumococcal disease
$598 vs. $11,494), the cost for the prevention of one hospitaliza-
ion due to inﬂuenza and pneumococcal disease is similar in both
rogrammes ($10,787 and $11,494 respectively). The vaccine cost
o prevent one death per year is less for the pneumococcal vaccine
rogramme ($49,972 vs. $74,801). They inferred that since the vac-
ine costs associated with hospitalization or death due to invasive
neumococcal disease were similar or cheaper than for inﬂuenza,
t is likely that a pneumococcal vaccine programme would also be
ikely to be cost effective in this age group [4].
Three other studies showed cost-effectiveness of inﬂuenza,
uman papilloma virus and HZ vaccines. Brydak and colleagues
ound that 57 persons of the elderly population would have to be
accinated to prevent a single case of inﬂuenza. They interpreted
heir ﬁndings by stating that the funding of routine inﬂuenza vac-
ination programmes would be a very cost-effectiveness approach
n this population [5]. Hillemanns and colleagues reported that a
otal 120 girls would have to be vaccinated to prevent a single case
f cervical cancer in Germany and considered the HPV vaccination
rogramme to be a cost-effective strategy when compared to cer-
ical screening alone [21]. Finally, a cost-effectiveness evaluation
f HZ vaccination in reducing HZ (shingles) and PHN in the elderly
n Belgium has found that NNV is 12 in order to prevent one case33 (2015) 753–758
of HZ; while it is 35 for PHN. It was  considered as a cost-effective
strategy in Belgium to vaccinate elderly aged 60 years and older
[16].
De Serres et al. estimated that 314,000 to 2.7 million persons
would have to be vaccinated to prevent a single case of rabies
acquired through bedroom bat exposure. Furthermore, 293–2500
health care providers would have to be vaccinated to prevent a
human case of rabies in the same setting. This study suggested
that the extensive resources required to prevent a single case of
rabies through post-exposure prophylaxis would be higher than
what would be considered reasonable [30].
3.3. Modelling designs
Two studies have used modelling simulations to calculate NNV
to estimate the impact of vaccination programmes. Using a mathe-
matical model Brisson et al. were able to calculate the NNV required
preventing HPV-associated outcomes and death. Their ﬁndings
suggest that among 12-year-old girls, eight are required to be vac-
cinated to prevent a single case of genital warts. Similarly, 324 girls
would have to be vaccinated to prevent a single case of cervical can-
cer. It is important to mention that these numbers were calculated
assuming that the HPV vaccine provides lifelong protection with
95% vaccine effectiveness. Based on their mathematical models, the
authors suggested that the current HPV immunization programme
could reduce the number of cases with genital warts and cervical
cancer [19]. In another study, Van Rie and Hethcote applied com-
puter programmes to compute NNV to estimate and compare the
effectiveness of ﬁve different immunization strategies. They found
that NNV to prevent a case of pertussis was  lowest for the ado-
lescent strategy, while the cocoon strategy had the lowest NNV to
prevent a single case in young infants [24].
4. Discussion
The NNV is often equated to the number-needed-to-treat (NNT)
metric, commonly used in assessing the effectiveness of a health-
care intervention. We  searched the literature to identify how
scholars utilized this metric and focused on the recommendations
and conclusions drawn from these studies. Broadly, NNV has been
used in the literature to describe three main domains: potential
impact of a given vaccination programme, cost-effectiveness and
economic analyses, and modelling studies to compare different
vaccination strategies.
Researchers who  calculated NNV to demonstrate potential ben-
eﬁts of particular vaccination programmes based their calculations
on risk difference or other similar formulae. Authors attempted
to compute NNV across different health endpoints [7,17,20], com-
pare different types of vaccines [6], estimate vaccination impact
in immune-compromised populations [8,11], assess the effect of
repeated vaccinations [9], and describe patient and physician
expectation about NNV [18]. As expected, most of the conclu-
sions drawn from this group of studies reported that vaccination
programmes that require a lower NNV are more beneﬁcial in com-
parison to programmes that necessitate higher NNV.
The second group used health economics to assess the cost-
effectiveness of different vaccination programmes. Some studies
used NNV as a metric to demonstrate the cost-effectiveness of
a particular vaccination programme and use this information to
make a policy recommendation, while other studies reported high
costs based on NNV calculations, challenging speciﬁc vaccination
programmes that were found to be resource intensive. The third
group used mathematical modelling and computer simulations to
calculate NNV to determine the beneﬁts and impact of different
vaccination strategies and health outcomes [19,24].
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NNV estimates varied widely between publications, likely relat-
ng to the fact that they are complex to calculate and are dependent
n several factors, including setting, population, disease preva-
ence, and the healthcare system in question. As a result, NNV
stimates are most relevant to the speciﬁc study group for which
hey are calculated, with a limited capacity for broader application.
hile this may  be useful in some circumstances, such as calcu-
ating cost effectiveness of two candidate vaccines for a speciﬁc
opulation, this brings into question whether NNV is an appropri-
te measure for use in public health. Few of the papers we reviewed
ully acknowledge the limitations of NNV, reinforcing the need for
aution and more agreement on when and how it is appropriate to
se this metric.
NNV is thought to be an intuitive measure of the effectiveness
f vaccination comparable to NNT. However, this comparison has
ot been evaluated and may  not be valid. When the NNT is used
o evaluate drugs, the direct costs and beneﬁts to the individual
re much clearer, may  apply to a shorter time period and occur
n close temporal relationship to exposure. This is not the case
or NNV, since vaccinations are preventative, effects may  be indi-
ect, and the extent and exact timing or extent of exposure is often
nknown. Kelly et al. argue that NNV is considered on an annual
asis because vaccine preventable diseases tend to have a short
ncubation period, a short course, and may  recur [4]. However, most
accination programmes are expected to carry on preventing cases
ver several years, revealing another limitation to NNV. Further-
ore, once diseases are approaching elimination, the NNV becomes
ery large and even misleading, since immunization cannot stop at
hat point.
These limitations were recently highlighted in a study that
ttempted to utilize NNV in mathematical models to calculate the
ndirect effects of vaccines, such as reduction in secondary cases
ue to fewer transmissible cases and the beneﬁts of herd immunity.
he study criticized the use of standard NNV calculations, ﬁnding
hat they tend to produce overestimated numbers when compared
o dynamic NNV calculations that incorporate the indirect effects of
he immunization programmes. The study concluded that standard
NV calculations undervalue the potential beneﬁts of vaccina-
ion programmes and should therefore be used and interpreted
ith caution [31]. Dynamic mathematical models are established
ssential tools for assessing the need and potential impact of vac-
ines, including their indirect effects. Such models are however
abour intensive and hard for non-modelers to understand. NNV
s a simpler measure, but its limitations used in isolation of more
ophisticated approaches need to be emphasized.
In conclusion, NNV has been used in a wide variety of ways in
he literature: to justify immunization programmes, to evaluate
ublic health or economic beneﬁts or to compare immunization
trategies. Its simplicity make it an appealing measure. However,
ethods for calculating NNV lack uniformity and there are no
eﬁned thresholds for what is a favourable NNV, making interpre-
ation and generalizability of this measure difﬁcult. Furthermore,
he NNV does not take into account the indirect effects of vacci-
ation, and so should be used with caution. Further discussion is
equired in order to reach a consensus on the appropriate use of
NV in evaluating vaccination programmes.
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